secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alaunos Therapeutics, Inc. (TCRT)
CIK:        0001107421
Form:       8-K
Filed at:   2026-05-18T12:00:43+00:00
Accession:  0001193125-26-227921
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alaunos announces preclinical ALN1003 data; cash only $0.354M, runway into Q2 2026
--------------------------------------------------------------------------------

- ALN1003 showed significantly lower HOMA-IR (p=0.0006) and higher adiponectin-to-leptin ratio in DIO mouse models.
- Blinded liver histology: ALN1003-treated mice had mean NAS scores of 2.7 and 1.3 vs control score of 5.
- Data are from non-GLP studies with small sample sizes; no human trials conducted yet.
- Cash and equivalents $0.354M as of March 31, 2026; company seeking additional financing.
- Plans to advance ALN1003 with further preclinical dose optimization and metabolic phenotyping.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1107421/000119312526227921/0001193125-26-227921-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1107421/000119312526227921/tcrt-20260302.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-227921

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer